phosphotyrosine has been researched along with thromboplastin in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Komiyama, Y; Masuda, M; Murakami, T; Nakamura, S; Takahashi, H | 1 |
| Chen, Z; Hu, Y; Huang, Y; Mao, L; Pan, H; Pan, J; Pan, X; Qian, S; Xu, S; Xu, W; Ye, Y; Yu, X | 1 |
2 other study(ies) available for phosphotyrosine and thromboplastin
| Article | Year |
|---|---|
Association of tissue factor with a gamma chain homodimer of the IgE receptor type I in cultured human monocytes.
Topics: Cells, Cultured; Factor VIIa; Humans; Macrophages; Monocytes; Phosphorylation; Phosphotyrosine; Protein Binding; Receptors, IgE; Signal Transduction; Thromboplastin | 1996 |
Phospho-Tyr705 of STAT3 is a therapeutic target for sepsis through regulating inflammation and coagulation.
Topics: Aminosalicylic Acids; Animals; Benzofurans; Blood Coagulation; Cecum; Cell Membrane Permeability; Endothelial Cells; Humans; Inflammation; Inflammation Mediators; Ligation; Lipopolysaccharides; Macrophages; Male; Mice; Mice, Inbred C57BL; Models, Biological; Molecular Targeted Therapy; Naphthoquinones; Phosphotyrosine; Punctures; RAW 264.7 Cells; Sepsis; STAT3 Transcription Factor; Sulfonamides; Suppression, Genetic; Survival Analysis; Thromboplastin; Toll-Like Receptor 4 | 2020 |